贵州百灵企业集团制药股份有限公司

GUIZHOU BAILING GROUP PHARMACEUTICAL LIMITED BY SHARE LTD

貴州百靈企業集團製藥股份有限公司是一家從事苗藥研發、生產、銷售於一體的醫藥上市公司，註冊資本14.112億元，總資產64.9億元，員工6000餘人。2010年6月，公司在深圳證券交易所成功上市（股票代碼：SZ002424）。公司明確圍繞“强化公司在苗藥領域的優勢地位，力爭成為中成藥領域具有覈心競爭優勢的企業”為戰略發展目標，致力打造擁有大健康全產業鏈的企業集團。

Guizhou Bailing Group Pharmaceutical Co., Ltd. (hereinafter referred to as “Guizhou Bailing”) is a listed pharmaceutical company which focuses on research & development, manufacture and marketing of Chinese Miao medicine, with a registered capital of 1.41 billion yuan, total assets of 6.49 billion yuan, and more than 6,000 employees. In June 2010, the company was successfully listed on the Shenzhen Stock Exchange (stock code: SZ 002424). Guizhou Bailing formulated the strategic development goal which is “strengthening the company’s dominant position in the field of Miao medicine and striving to be an enterprise with core competitive advantages in the field of Chinese Traditional Patent Medicine”.The company takes the implementation of “scientific and technological Miao medicine, cultural Miao medicine and ecological Miao medicine” as the starting point and strives to build an enterprise group with a complete industrial chain of enlarged health industry.

中药、苗药产品

dominant products of Miao medicine and traditional Chinese medicine